Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is also hampering Kymriah sales.